摘要
目的研究红花多糖通过阻断PI3K/Akt/mTOR通路诱导人乳腺癌MDA-MB-435细胞凋亡的作用及其作用机制。方法将MDA-MB-435细胞分为对照组和红花多糖0.5、1.0 mg/mL组。MTT法及流式检测仪分别检测不同质量浓度红花多糖对MDA-MB-435细胞生长及凋亡的影响;RT-PCR及Western blotting法分别检测不同质量浓度红花多糖对MDA-MB-435细胞PI3K、Akt、mTOR mRNA和蛋白表达的影响。结果与对照组比较,红花多糖0.5 mg/mL组MDA-MB-435细胞抑制率为(21.52±2.43)%,红花多糖1.0 mg/mL组细胞抑制率为(27.73±3.75)%,显著高于红花多糖0.5 mg/m L组(P<0.05);与对照组比较,红花多糖能够显著提高MDA-MB-435细胞凋亡率(P<0.01),且呈剂量依赖性。RT-PCR及Western blotting实验结果显示,与对照组比较,红花多糖能够使MDA-MB-435细胞中PI3K、Akt、mTOR mRNA和蛋白表达显著降低(P<0.05、0.01)。结论红花多糖能有效抑制MDA-MB-435细胞的生长,促进其凋亡,作用可能是通过对PI3K/Akt/mTOR通路的阻断实现的。
Objective To investigate the effect of safflower polysaccharide on apoptosis of human breast cancer MDA-MB-435 cells by blocking PI3K/Akt/mTOR pathway and explore its mechanism. Methods MDA-MB-435 cells were divided into control group and safflower polysaccharide 0.5 and 1.0 mg/mL groups. MTT assay and flow cytometry were used to detect the effects of different concentrations of safflower polysaccharide on the growth inhibition and apoptosis of MDA-MB-435 cells. RT-PCR and Western blotting were used to detect the effect of different concentrations of safflower polysaccharides on the mRNA and protein expression of PI3K, Akt, and mTOR in MDA-MB-435 cells. Results Compared with the control group, the inhibition rate of MDA-MB-435 cells in safflower polysaccharide 1.0 mg/mL group was(27.73 ± 3.75)%, which was significantly higher than that [(21.52 ± 2.43)%] in safflower polysaccharide 0.5 mg/mL group(P〈0.05). Compared with the control group, safflower polysaccharide could significantly increase the apoptosis rate of MDA-MB-435 cells in a dose-dependent manner(P〈0.01). The results of RT-PCR and Western blotting showed that, compared with the control group, safflower polysaccharide significantly decreased the mRNA and protein expression of PI3K, Akt, and mTOR in MDA-MB-435 cells(P〈0.05, 0.01). Conclusion Safflower polysaccharide can effectively inhibit the growth of MDA-MB-435 cells and promote their apoptosis, which may be achieved by blocking the PI3K/Akt/mTOR pathway.
作者
刘楠
朱琳
李纳
张晓坚
LIU Nan;ZHU Lin;LI Na;ZHANG Xiao-jian(Department of Pharmacy,The First Affiliated Hospital of Zhengzhou University,Zhengzhou 450000,China)
出处
《中草药》
CAS
CSCD
北大核心
2018年第18期4374-4379,共6页
Chinese Traditional and Herbal Drugs
基金
国家自然科学基金面上项目(31570357)
河南省高等学校重点科研项目计划(15A350016)